INM
InMed Pharmaceuticals Inc.
NASDAQ · CAHealthcareBiotechnology
$1.52-1.30%
Price as of Jul 20, 2026
INM profitability
InMed Pharmaceuticals Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 30.4%
- EBITDA margin
- -229.5%
- EBIT margin
- -246.8%
- Net margin
- -246.4%
- Free cash flow margin
- -223.9%
Returns
- Return on equity
- -143.8%
- Return on assets
- -108.5%
- Return on invested capital
- -135.8%
- Asset turnover
- 0.33x
Cash efficiency
- Cash from operations
- -$9.0M
- Cash per share
- $1.57
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.